Nothing Special   »   [go: up one dir, main page]

CN113840841A - 靶向cd19的全人源抗体及其应用 - Google Patents

靶向cd19的全人源抗体及其应用 Download PDF

Info

Publication number
CN113840841A
CN113840841A CN202080037449.9A CN202080037449A CN113840841A CN 113840841 A CN113840841 A CN 113840841A CN 202080037449 A CN202080037449 A CN 202080037449A CN 113840841 A CN113840841 A CN 113840841A
Authority
CN
China
Prior art keywords
amino acid
acid sequence
cells
antibody
car
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080037449.9A
Other languages
English (en)
Other versions
CN113840841B (zh
Inventor
谭涛超
戴振宇
贾向印
魏巧娥
杨永坤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Reindeer Biotechnology Co ltd
Original Assignee
Nanjing Iaso Biotherapeutics Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Iaso Biotherapeutics Technology Co ltd filed Critical Nanjing Iaso Biotherapeutics Technology Co ltd
Priority to CN202310120560.XA priority Critical patent/CN116589579A/zh
Publication of CN113840841A publication Critical patent/CN113840841A/zh
Application granted granted Critical
Publication of CN113840841B publication Critical patent/CN113840841B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

提供了靶向CD19的全人源抗体或其单链抗体或片段。还提供了采用来自该全人源抗体的单链抗体(scFv)构建的嵌合抗原受体(CAR)。该全人源抗体和CAR可用于靶向CD19的CAR‑T细胞的构建。与采用鼠源抗体的CAR‑T细胞相比，所述的CAR‑T细胞与人体具有更好的相容性，有利于其在体内的长期增殖和存活。

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN202080037449.9A 2019-05-20 2020-05-20 靶向cd19的全人源抗体及其应用 Active CN113840841B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310120560.XA CN116589579A (zh) 2019-05-20 2020-05-20 靶向cd19的全人源抗体及其应用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019104190898 2019-05-20
CN201910419089 2019-05-20
PCT/CN2020/091235 WO2020233589A1 (zh) 2019-05-20 2020-05-20 靶向cd19的全人源抗体及其应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310120560.XA Division CN116589579A (zh) 2019-05-20 2020-05-20 靶向cd19的全人源抗体及其应用

Publications (2)

Publication Number Publication Date
CN113840841A true CN113840841A (zh) 2021-12-24
CN113840841B CN113840841B (zh) 2023-03-07

Family

ID=73458076

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202310120560.XA Pending CN116589579A (zh) 2019-05-20 2020-05-20 靶向cd19的全人源抗体及其应用
CN202080037449.9A Active CN113840841B (zh) 2019-05-20 2020-05-20 靶向cd19的全人源抗体及其应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202310120560.XA Pending CN116589579A (zh) 2019-05-20 2020-05-20 靶向cd19的全人源抗体及其应用

Country Status (7)

Country Link
US (1) US20220220200A1 (zh)
EP (1) EP3974452A4 (zh)
JP (1) JP7566352B2 (zh)
CN (2) CN116589579A (zh)
AU (1) AU2020277525A1 (zh)
CA (1) CA3141498A1 (zh)
WO (1) WO2020233589A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114891108A (zh) * 2022-05-30 2022-08-12 上海驯鹿生物技术有限公司 一种靶向bcma的全人源抗体及其应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230241212A1 (en) * 2020-06-30 2023-08-03 Nanjing Iaso Biotherapeutics Co., Ltd. Fully humanized bispecific chimeric antigen receptor targeting cd19 and cd22 and use thereof
WO2022257984A1 (zh) * 2021-06-08 2022-12-15 南京驯鹿医疗技术有限公司 一种增强型嵌合抗原受体(car)细胞的制备及其应用
WO2024182516A1 (en) 2023-02-28 2024-09-06 Juno Therapeutics, Inc. Cell therapy for treating systemic autoimmune diseases
WO2024206897A1 (en) * 2023-03-30 2024-10-03 Cabaletta Bio, Inc. Methods and compositions for treating autoimmune diseases

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007002223A2 (en) * 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
CN101233156A (zh) * 2005-06-20 2008-07-30 米德列斯公司 Cd19抗体及其用途
WO2009054863A2 (en) * 2006-12-13 2009-04-30 Medarex, Inc. Human antibodies that bind cd19 and uses thereof
CN104558181A (zh) * 2014-12-31 2015-04-29 四川大学 靶向b淋巴瘤细胞的人源单链抗体
CN106554414A (zh) * 2015-09-18 2017-04-05 科济生物医药（上海）有限公司 抗cd19全人抗体以及靶向cd19的免疫效应细胞
CN107531793A (zh) * 2015-10-13 2018-01-02 优瑞科生物技术公司 对人类cd19具有专一性的抗体药剂和其用途
CN107880128A (zh) * 2017-12-21 2018-04-06 常州费洛斯药业科技有限公司 一种抗cd19的全人源抗体或抗体片段及其方法和应用
CN109293774A (zh) * 2018-10-16 2019-02-01 南京医科大学 特异性结合cd19的全人源化抗体及应用

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007002223A2 (en) * 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
CN101233156A (zh) * 2005-06-20 2008-07-30 米德列斯公司 Cd19抗体及其用途
WO2009054863A2 (en) * 2006-12-13 2009-04-30 Medarex, Inc. Human antibodies that bind cd19 and uses thereof
CN101636502A (zh) * 2006-12-13 2010-01-27 梅达雷克斯公司 结合cd19的人类抗体及其用途
CN104558181A (zh) * 2014-12-31 2015-04-29 四川大学 靶向b淋巴瘤细胞的人源单链抗体
CN106554414A (zh) * 2015-09-18 2017-04-05 科济生物医药（上海）有限公司 抗cd19全人抗体以及靶向cd19的免疫效应细胞
CN107531793A (zh) * 2015-10-13 2018-01-02 优瑞科生物技术公司 对人类cd19具有专一性的抗体药剂和其用途
CN107880128A (zh) * 2017-12-21 2018-04-06 常州费洛斯药业科技有限公司 一种抗cd19的全人源抗体或抗体片段及其方法和应用
CN109293774A (zh) * 2018-10-16 2019-02-01 南京医科大学 特异性结合cd19的全人源化抗体及应用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114891108A (zh) * 2022-05-30 2022-08-12 上海驯鹿生物技术有限公司 一种靶向bcma的全人源抗体及其应用
CN114891108B (zh) * 2022-05-30 2022-11-15 上海驯鹿生物技术有限公司 一种靶向bcma的全人源抗体及其应用

Also Published As

Publication number Publication date
EP3974452A4 (en) 2023-08-23
US20220220200A1 (en) 2022-07-14
WO2020233589A9 (zh) 2021-03-25
AU2020277525A1 (en) 2022-01-20
CN116589579A (zh) 2023-08-15
EP3974452A1 (en) 2022-03-30
JP7566352B2 (ja) 2024-10-15
JP2022534135A (ja) 2022-07-27
CA3141498A1 (en) 2020-11-26
WO2020233589A1 (zh) 2020-11-26
CN113840841B (zh) 2023-03-07

Similar Documents

Publication Publication Date Title
CN113840841B (zh) 靶向cd19的全人源抗体及其应用
CN108124445B (zh) Ctla4抗体、其药物组合物及其用途
CN107973854B (zh) Pdl1单克隆抗体及其应用
EP2215121B1 (en) Anti-mesothelin antibodies and uses therefor
US10927176B2 (en) Tumor-specific anti-EGFR antibody and application thereof
CN111848800B (zh) Pd-l1单结构域抗体及其用途
CN109942708B (zh) 一种抗bcma的单域抗体及其应用
AU2020281380B2 (en) Antibody or chimeric antigen receptor which targets claudin 18.2
CN112062851B (zh) 靶向bcma嵌合抗原受体的抗体及其应用
JP2020037571A (ja) Ｔｍｃｃ３の阻害による、癌を抑制するための方法
CN112745391B (zh) Pd-l1结合分子
CN110156895B (zh) 一种抗pd-l1抗体或其功能性片段及其用途
CN113912731A (zh) 一种抗fgl1抗体及其应用
JP7245358B2 (ja) 抗ｃｄ２５抗体及びその適用
CN113501879B (zh) 一种解除肿瘤免疫微环境中免疫抑制的双功能抗体及其应用和制备方法
CN115386007A (zh) 抗gprc5d抗体、其制备方法与用途
Studennikov et al. New human single chain anti-idiotypic antibody against benzo [a] pyrene
CN115867353A (zh) 抗lilrb1抗体及其用途
CN116234559A (zh) 抗cd22单结构域抗体和治疗性构建体
CN115124620B (zh) 一种能够激活nk细胞的抗体及其应用
EP4063387A1 (en) Psma antibody and use thereof
EP4059962A1 (en) Pd-l1 binding molecule
Zhou et al. Antibody Recognition of Human Epidermal Growth Factor Receptor-2 (HER2) Juxtamembrane Domain Enhances Anti-Tumor Response of Chimeric Antigen Receptor (CAR)-T Cells
CN116568709A (zh) 靶向cd5的全人源抗体、全人源嵌合抗原受体（car）及其应用
성준식 Development and Characterization of Monoclonal Antibody Specific to Oncogenic Variant AIMP2-DX2

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: 210000 10 / F, building D, phase II, Zhongdan Ecological Life Science Industrial Park, No. 3-1, xinjinhu Road, Jiangbei new district, Nanjing City, Jiangsu Province

Patentee after: Nanjing Reindeer Biotechnology Co.,Ltd.

Address before: 210000 10 / F, building D, phase II, Zhongdan Ecological Life Science Industrial Park, No. 3-1, xinjinhu Road, Jiangbei new district, Nanjing City, Jiangsu Province

Patentee before: NANJING IASO BIOTHERAPEUTICS TECHNOLOGY Co.,Ltd.

CP01 Change in the name or title of a patent holder